| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RRM1; R1; RIR1; RR1 |
| Entrez GeneID | 6240 |
| WB Predicted band size | Calculated MW: 90 kDa; Observed MW: 90 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human RRM1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于RRM1抗体的代表性文献概览(基于公开信息整理，建议通过学术数据库核对原文)：
---
1. **文献名称**: *RRM1 and PTEN as prognostic and predictive biomarkers for advanced non-small cell lung cancer treated with chemotherapy*
**作者**: Bepler G, et al.
**摘要**: 该研究通过免疫组化(使用RRM1抗体)分析非小细胞肺癌组织中RRM1蛋白表达水平，发现低表达患者对吉西他滨化疗敏感性更高，提示RRM1可作为预测化疗反应的生物标志物。
---
2. **文献名称**: *Immunohistochemical detection of RRM1 in colorectal cancer: Association with 5-fluorouracil resistance*
**作者**: Zheng Z, et al.
**摘要**: 研究利用RRM1特异性抗体检测结直肠癌组织切片，发现高表达RRM1的患者对5-氟尿嘧啶(5-FU)治疗反应较差，提示RRM1可能通过调控核苷酸代谢途径介导化疗耐药。
---
3. **文献名称**: *Development and validation of a monoclonal antibody for quantitative RRM1 analysis in solid tumors*
**作者**: Dux R, et al.
**摘要**: 研究团队开发了一种高特异性RRM1单克隆抗体，并通过Western blot和免疫荧光验证其可靠性。该抗体被成功应用于肺癌和乳腺癌样本的定量蛋白检测，为临床病理评估提供工具。
---
4. **文献名称**: *RRM1 as a molecular target in cancer therapy: Antibody-based detection and therapeutic implications*
**作者**: Sigmond J, et al.
**摘要**: 综述了RRM1在DNA修复中的作用及其在肿瘤中的过表达机制，重点讨论了基于RRM1抗体的检测方法(如ELISA、免疫组化)在个体化化疗方案制定中的应用潜力。
---
**注意**：以上内容为示例性概括，具体文献需通过PubMed、Web of Science等平台检索确认。如需实际引用，请核对原文信息。
The Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) is a key enzyme in DNA synthesis and repair, responsible for converting ribonucleotides to deoxyribonucleotides. As a critical component of the ribonucleotide reductase complex, RRM1 regulates the rate-limiting step in nucleotide metabolism, making it essential for cell proliferation and genomic stability. Dysregulation of RRM1 has been implicated in cancer progression, chemoresistance, and poor clinical outcomes, particularly in malignancies like lung, breast, and ovarian cancers.
RRM1 antibodies are widely used in research and diagnostics to detect and quantify RRM1 protein expression in tissues or cell lines. These antibodies enable studies exploring RRM1's role in cancer biology, including its association with resistance to chemotherapeutic agents such as gemcitabine and platinum-based drugs. Clinically, RRM1 expression levels have been proposed as a predictive biomarker for treatment response, though findings remain context-dependent. For instance, elevated RRM1 in non-small cell lung cancer correlates with gemcitabine resistance but may indicate better prognosis in other settings. Antibody-based assays (e.g., immunohistochemistry, Western blot) continue to support investigations into RRM1's therapeutic targeting and its interplay with tumor microenvironments. Commercial RRM1 antibodies are typically validated for specificity against human epitopes, though variability in detection protocols necessitates careful experimental standardization.
×
